Lung Cancer Clinical Trials

A listing of Lung Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 27 clinical trials
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

The purpose of this study is to find if adding the study drug, nivolumab (also known as OPVIDO), will limit lung cancer from growing back in patients with early stage non-small cell lung cancer. Nivolumab is a drug that may turn on the body's immune system to attack any cancer …

  • 0 views
  • 19 Feb, 2024
  • 1 location
Intratumoral Gene Mediated Cytotoxic Immunotherapy (GMCI) For Resectable Non-Small Cell Lung Cancer

Surgery is the best treatment for patients with Stage I or II lung cancer; however, nearly 60% of patients have recurrence. Additional immunotherapeutic agents given before surgery may be greatly reduce recurrence.

  • 0 views
  • 19 Feb, 2024
  • 1 location
UPCC 09517: Phase II study of Pembrolizumab and Itacitinib (INCB039110) for First Line Treatment of Metastatic Non-Small Cell Lung Cancer Expressing PD-L1

The main purpose of this study is to examine the efficacy of adding itacitinib (also known as INCB039110) to pembrolizumab in patients with previously untreated metastatic non-small cell lung cancer.

  • 0 views
  • 19 Feb, 2024
  • 1 location
UPCC 16520: A Phase Ib-II Trial of Tocilizumab and Atezolizumab in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

This is an investigator-initiated, open label phase Ib study examining 2nd line atezolizumab and tocilizumab in a cohort of recurrent/metastatic non-small cell lung cancer patients who have received prior immune checkpoint inhibitor therapy with or without other forms of therapy (i.e. chemotherapy, radiation).

  • 0 views
  • 19 Feb, 2024
  • 1 location
UPCC 15518 / ANAM-17-21: A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

The main purpose of this study is to learn more about how well the experimental drug, anamorelin hydrochloride (HCl), works to prevent weight loss and anorexia in patients with advanced Non-Small Cell Lung Cancer.

  • 0 views
  • 19 Feb, 2024
  • 1 location
UPCC 21520: The LIMIT KRAS Mutant NSCLC Trial: Lysosome Inhibition to Enhance MAPK Inhibition Targeting KRAS Mutant NSCLC: A Phase 2 Open Label Trial of Binimetinib and Hydroxychloroquine in Patients with Advanced KRAS Mutant Non-Small Cell Lung Cancer

The dose of HCQ will also be fixed based on ongoing phase I studies. Eligible subjects will have lung cancer that has a mutation in a key cancer gene called KRAS, and the cancer has spread to other parts of their body.

  • 0 views
  • 19 Feb, 2024
  • 1 location
AN UN-BLINDED INTRA-PATIENT COMPARISON OF TRANSBRONCHIAL FORCEPS BIOPSY AND CRYOBIOPSY FOR PERIPHERAL PULMONARY LESIONS

Peripheral lung nodules seen on CT scans require a diagnostic evaluation as they commonly represent small, treatable lung cancers. In order to diagnose these lung lesions, bronchoscopy with small lung biopsies is often the preferred first step. However, this procedure is not always successful as not all biopsies obtain enough …

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Phase 1 Study of the Highly-selective RET

This is a phase 1 study with Highly-selective RET inhibiter, Blu-667, in patients with Thyroid Cancer, Non-Small cell lung cancer and other advanced solid tumors. The study will be conducted at multiple centers in the United States and Europe. the purpose of this trial is to determine the maximum tolerated …

  • 0 views
  • 19 Feb, 2024
  • 1 location
Substudy: Understanding COVID-19 vaccine responses in the setting of immunotherapy

Anti-PD-1 antibody infusion is now increasingly being tested for other cancers as well, with relatively recent FDA-approval for use in metastatic non-small cell lung cancer, renal cell carcinoma, and metastatic or recurrent head and neck squamous cell carcinoma. This study is designed to better understand antibody responses in the setting …

  • 0 views
  • 19 Feb, 2024
  • 1 location
Pragmatic Clinical Trial Comparing Smoking Cessation Interventions among Underserved Patients who are referred for Lung Cancer Screening

Low-dose computed tomography (LDCT) screening reduces mortality among current and former smokers at high risk for lung cancer, and is widely recommended by national guidelines. LDCT also increases access to care and thus provides an opportunity to deliver smoking cessation interventions to current smokers in conjunction with this screening.

  • 0 views
  • 19 Feb, 2024
  • 1 location